



Contents lists available at ScienceDirect

American Journal of Emergency Medicine

journal homepage: www.elsevier.com/locate/ajemThe
American Journal of
Emergency Medicine

Original Contribution

Assessment of acute asthma severity in the ED: are heart and respiratory rates relevant? ☆☆☆

Gustavo J. Rodrigo, MD ^{a,1}, Hugo Neffen, MD ^{b,*}^a Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Av 8 de Octubre 3020, Montevideo 11300, Uruguay^b Unidad de Medicina Respiratoria, Hospital de Niños "O Allasia", Santa Fe, Argentina

ARTICLE INFO

Article history:

Received 6 May 2015

Received in revised form 11 June 2015

Accepted 13 June 2015

Available online xxxxx

ABSTRACT

Background: Assessment of acute asthma severity in the emergency department (ED) determines the appropriate initial therapy. The aim of this study was to evaluate the usefulness of heart and respiratory rates as determinants of severity of asthma exacerbations.

Methods: It was a pooled analysis of individual patient data from different controlled clinical trials performed over a 9-year period. The sample was characterized by patients with a diagnosis of asthma, age 18 to 50 years, and a forced expiratory volume in the first second (FEV₁) or a peak expiratory flow less than or equal to 50% of predicted at ED presentation.

Results: One thousand one hundred ninety-two severe acute asthmatics (age 33.9 ± 10.3 years and FEV₁ = 27.4% ± 9.7%) were enrolled. Two-thirds of patients were categorized as having severe acute asthma (FEV₁, 31%–50% of predicted) and the remaining third as life-threatening asthma (FEV₁, ≤30% of predicted). There were no relationships between the intensity of airway obstruction as measured by the FEV₁ and the degree of tachycardia ($r = 0.05$, $P > .1$) or tachypnea ($r = 0.06$, $P > .1$). Only 22% and 19% of the patients, respectively, met the heart rate and respiratory rate requirements for acute severe asthma (≥120/min and ≥25/min, respectively). In contrast to FEV₁ and arterial oxygen saturation, baseline heart and respiratory rates did not predict admissions of patients at the end of treatment.

Conclusions: This pooled analysis suggests a poor performance of heart and respiratory rates as determinants of acute asthma severity in the ED.

© 2015 Elsevier Inc. All rights reserved.

1. Introduction

All patients with asthma are at risk for having exacerbations characterized by progressive increases in shortness of breath, cough, wheezing, chest tightness, along with a decrease in expiratory airflow [1,2]. The severity of exacerbations may range from mild to life threatening, and deterioration mostly progresses over hours, days, or weeks. Overall, the assessment of an asthma exacerbation in the emergency department (ED) constitutes a process with 2 different steps: firstly, a static assessment to determine the severity of attack and, secondly, a dynamic assessment to evaluate the response to treatment [1–6]. Regarding the first step, patients should be evaluated quickly because the severity of the exacerbation determines the appropriate initial therapy. Although spirometry is the primary determinant of severity, different symptoms and signs are additionally used to categorize asthma exacerbations. [7–9] Hence,

asthma management guidelines include heart and respiratory rates as a part of the severity evaluation of acute exacerbations. For example, the Global Initiative for Asthma guidelines [7] establish that tachycardia (>120/min) and tachypnea (>30/min) are vital signs that characterized severe exacerbations. In a similar way, a heart rate greater than or equal to 110/min and a respiratory rate greater than or equal to 25/min are indicators of severe acute asthma according to the British guideline on the management of asthma [8]. However, these recommendations are poorly supported by scientific evidence and have rarely been verified in clinical practice.

The aim of this study was to evaluate the usefulness of heart and respiratory rates as determinants of severity of acute asthma in the ED setting, through a pooled analysis of individual patient data from a large cohort of acute asthmatic patients.

2. Methods

2.1. Study population

This was a pooled analysis of individual patient data from different controlled clinical trials performed over a 9-year period. Patients were adults with acute asthma who had attended the ED of a tertiary-care general hospital in Montevideo, Uruguay. The characteristics of the

☆ Author disclosures of conflicts of interest: Drs Rodrigo and Neffen have no financial or other potential conflicts of interest related with the objective of this research.

☆☆ Funding source: No sponsorship from institutions or pharmaceutical industry was provided to conduct this study.

* Corresponding author.

E-mail addresses: gustavo.javier.rodrigo@gmail.com (G.J. Rodrigo), hugoneffen@arnet.com.ar (H. Neffen).

¹ Tel.: +598 2708 2354; fax: +598 2900 6313.

cohort and the selection criteria used are described in detail elsewhere [9–15]. Briefly, the following sample was quite homogeneous: (1) patients with a diagnosis of asthma according to the guidelines; (2) age 18 to 50 years; (3) a forced expiratory volume in the first second (FEV₁) or a peak expiratory flow (PEF) less than or equal to 50% of predicted at ED presentation; and (4) absence of history of chronic cough and cardiac, hepatic, renal, or other medical disease or pregnancy. All participants gave their informed written consent to participate, and each study was approved by its respective ethics committee.

2.2. Protocol

All patients were treated with albuterol, 4 puffs at 10-minute intervals (100 mg per actuation), delivered by a metered-dose inhaler and a spacer device (Volumatic; Allen & Hansbursys, Greenford, United Kingdom). In 2 of the studies, patients received also ipratropium bromide [10,13]. In all studies, exacerbation treatment lasted 3 hours and also included the administration of systemic corticosteroids and O₂ if arterial oxygen saturation (Sao₂) decreased to less than 92%. Aminophylline was excluded in all studies. Patients from 3 of the studies also received inhaled corticosteroids added to albuterol [9,12,14]. At the end of protocol, patients were discharged from the ED according the following criteria: if accessory muscle use was abated, if wheezing was judged to be minimal or completely resolved, if patients were free of dyspnea, and if FEV₁ or PEF was greater than or equal to 60% of predicted.

2.3. Variables

The following variables were measured in each patient immediately before starting treatment and at 30-minute intervals for 3 hours after presentation to the ED: FEV₁, PEF, respiratory rate, heart rate, and oxygen saturation by pulse oximetry while breathing room air. Furthermore, an interviewer determined the duration of symptoms before presentation to the ED, age, sex, and body mass index of each patient.

2.4. Statistical methods

Mean values $\pm$ SD and 95% confidence intervals (CIs) were calculated for all continuous variables. Data were compared by 1-way or repeated-measures analysis of variance (ANOVA). χ^2 test with Yates correction or Fisher exact test was used for categorical variables. Finally, logistic regression was used to predict hospitalization from baseline variables. A *P* value of less than .05 using a 2-tailed test was taken as being of significance for all statistical tests. Data were analyzed with “IBM SPSS Statistics version 20 for Windows (SPSS Inc, Chicago, IL)”.

3. Results

We found 1192 patients fulfilling the data set required for inclusion in the analysis (Table). The sample presents the typical features of severe acute asthma patients when they presented for care to an ED—on average, a mean age approximately equal to 30 years old, predominantly female, with a mean level of lung function (FEV₁ or PEF) around 30% of predicted, tachycardia, tachypnea, and a Sao₂ greater than or equal to 95%. Two-thirds of patients were categorized as having severe acute asthma (FEV₁, 31%–50% of predicted) and the remaining third as life-threatening asthma (FEV₁, $\leq$ 30% of predicted). At baseline, the univariate analysis showed that those patients with severe acute asthma were predominantly female, had a significantly longer duration of symptoms before the ED treatment, and, obviously, presented with significantly higher spirometric values, in comparison with life-threatening asthma patients (Table). On the contrary, both groups did not differ in heart and respiratory rates and Sao₂. Accordingly, there were no relationships between the intensity of airway obstruction as measured by FEV₁ and the degree of tachycardia ($r = 0.05$, $P > .1$) or tachypnea ($r = 0.06$, $P > .1$). Fig. 1 shows the baseline distribution of heart and respiratory rates in the sample of patients with acute asthma. They showed an average of 102.8 ± 17.1 beats per minute (range, 60–160) and 22.0 ± 4.9 breaths per minute (range, 12–36), respectively. Only 22% and 19% of the patients met the requirements for acute severe asthma (≥ 120 /min and ≥ 25 /min, respectively).

Table
Characteristics of all patients included stratified by severity of exacerbation (severe vs life threatening)

Measures	Total (n = 1192)	Severe acute asthma ^b (n = 748)	Life-threatening asthma ^c (n = 444)	Difference (95% CI)	<i>P</i>
At ED presentation					
Age, y ^a	33.9 (10.03)	33.7 (10.5)	34.3 (9.1)	0.6 (−0.5 to 1.7)	.31
Female, n (%)	780 (65.4)	436 (55.9)	344 (44.1)	−19.2 (−24.3 to 13.8)	.0001
BMI ^a	24.3 (4.8)	24.5 (4.5)	24.1 (4.9)	−0.4 (−0.9 to 0.1)	.20
Duration of symptoms before ED presentation, h ^a	30.9 (23.9)	32.3 (24.0)	28.5 (23.7)	−3.8 (−6.6 to −0.9)	.008
Heart rate/min ^a	102.8 (17.1)	102.8 (16.7)	102.8 (17.7)	0.0 (−2.0 to 2.0)	.99
Respiratory rate/min ^a	22.0 (4.9)	22.2 (5.3)	21.8 (4.4)	−0.4 (−0.9 to 0.1)	.49
PEF, % predicted ^a	33.1 (7.9)	38.0 (5.0)	24.8 (4.0)	−13.2 (−13.7 to −12.6)	.0001
PEF, L/min ^a	172.5 (48.4)	200.0 (36.1)	126.1 (25.9)	−73.9 (−77.7 to −70.0)	.0001
FEV ₁ , % predicted ^a	27.4 (9.7)	30.2 (9.2)	22.8 (8.7)	−7.4 (−8.4 to −6.3)	.0001
FEV ₁ , L ^a	0.8 (0.3)	1.0 (0.3)	0.6 (0.2)	−0.4 (−0.4 to −0.3)	.0001
Sao ₂ ^a	95.4 (1.8)	95.4 (1.8)	95.6 (1.8)	0.2 (0.0 to 0.4)	.22
At the end of ED treatment					
PEF, % predicted ^a	64.5 (16.2)	67.6 (14.9)	59.3 (16.9)	−8.3 (−10.1 to −6.4)	.0001
Change from baseline in PEF, L/min ^a	157.3 (72.5)	151.3 (74.6)	168.7 (76.4)	17.4 (8.5 to 26.2)	.0001
FEV ₁ , % predicted ^a	59.8 (19.1)	61.2 (17.5)	57.6 (21.2)	−3.6 (−5.8 to −1.3)	.002
Change from baseline in FEV ₁ , L ^a	1.1 (1.2)	1.0 (1.3)	0.7 (0.9)	−0.3 (−0.1 to −0.4)	.001
Change from baseline in heart rate/min ^a	3.0 (2.3)	4.5 (3.1)	0.8 (0.5)	−3.7 (−3.9 to 3.4)	.0001
Change from baseline in respiratory rate/min ^a	−3.0 (2.5)	−3.2 (2.4)	−2.8 (2.3)	0.4 (0.0 to 0.7)	.01
Change from baseline in Sao ₂ ^a	1.2 (0.9)	0.7 (0.6)	1.8 (1.2)	1.1 (1.0 to 1.2)	.0001
Hospital admissions, n (%)	188 (15.8)	104 (13.9)	84 (18.9)	−5.0 (−7.0 to −9.0)	.02

Abbreviations: BMI, body mass index.

^a Mean values $\pm$ (1 SD).

^b Forced expiratory volume in the first second less than or equal to 50% to greater than 30% of predicted.

^c Forced expiratory volume in the first second less than or equal to 30% of predicted.




Fig. 1. Distribution of baseline heart (A) and respiratory rates (B) in the sample of patients with acute asthma ($n = 1192$).

Based on previously determined criteria, 104 patients (13.9%) with severe acute asthma required hospital admission compared with 84 patients (18.9%) with life-threatening asthma ($P = .02$). Data showed significant variations along the treatment for FEV₁, heart and respiratory rates, and Sao₂ (Fig. 2). Repeated-measures ANOVA indicates that only FEV₁ and Sao₂ presented significant differences across treatment in terms of the final outcome (discharged or admitted). According to the latter, logistic regression revealed that the same baseline variables were predictors of hospitalization at the end of treatment (FEV₁, percentage of predicted [odds ratio {OR} = 1.21; 95% CI, 1.18–1.25; $P = .01$] and Sao₂ [OR = 1.34; 95% CI, 1.30–1.38; $P = .006$]). By contrast, baseline heart and respiratory rates did not predict admissions (OR = 1.01 [95% CI, 0.98–1.04; $P = .13$] and OR = 1.02 [95% CI, 0.93–1.11; $P = .63$], respectively).

4. Discussion

Assessment of acute asthma severity in the ED is very important because it determines the appropriate initial therapy. Although spirometry is recognized as the major determinant of the severity, the assessment also includes different patient's features such as appearance, difficulty speaking, and respiratory and heart rates. More precisely, guidelines define a severe episode of asthma when one or more of the following features are present: accessory muscle activity, a paradoxical pulse exceeding 25 mm Hg, a heart rate greater than 110 to 120 beats per minute, a respiratory rate greater than 25 to 30 breaths per minute, a limited ability to speak, a PEF or FEV₁ less than 50% of predicted, and an arterial saturation less than 91% to 92% [7,8]. In addition, a PEF or




Fig. 2. Forced expiratory volume in the first second (percentage of predicted), heart rate, respiratory rate, and Sao₂ values over 3 hours of treatment according to final outcome of patients (■, discharged patients; ●, admitted patients). Brackets represent 1 SD. *Repeated-measures ANOVA.

FEV₁ less than or equal to 30% of predicted is considered to represent a life-threatening episode [8]. However, some of these indicators are the result of consensus because there is no evidence supporting them: this is the case of heart and respiratory rates. Moreover, it is difficult to understand why guidelines preserve these recommendations when the poor performance of these variables is known for at least 30 years [16].

The results of this pooled analysis of individual patient data from a large cohort of asthmatics suggest that both heart and respiratory rates measured at baseline have little value as determinants of the severity of acute asthma. Firstly, there was no relationship between the severity of airway obstruction and the degree of tachycardia or tachypnea. Heart and respiratory rates did not show significant differences between severe and life-threatening asthma patients. Bearing in mind that the sample consisted of patients with an FEV₁ less than 50%, only 20% of patients met the requirements for acute severe asthma. And, secondly, in the case that the severity definition is performed in terms of outcome rather than in terms of the initial patient presentation, the performance of heart and respiratory rates was also poor. Thus, both variables measured at baseline were not predictors of patient hospitalization or discharge; only baseline FEV₁ and Sao₂ showed significant differences in terms of the final outcome of patients.

This study highlights the central role of spirometry as the primary determinant of acute asthma severity in the ED setting. Peak expiratory flow or FEV₁ are valid triage tools to prioritize the severity of a patient's condition and the timing of care in the ED [5]. However, measurements of airflow obstruction are generally underutilized [17] despite their ease of performance [18]. Furthermore, acute asthma patients show differences in responsiveness to treatment related to different factors including the degree of airway inflammation, the presence or absence of mucus plugging, and the individual responsiveness to β_2 -adrenergic and corticosteroid medications [19,20]. Again, clinical evidence demonstrates that spirometry at the first hour of treatment predicts the requirement of hospital admission for acute asthma patients in the ED [21–24]. By contrast, heart rate and respiratory rates do not seem relevant in both steps of the evaluation of acute asthma patients.

Finally, although data for this study were collected retrospectively, they come from a set of studies with very similar protocols in terms of age, initial severity, inclusion/exclusion criteria, and therapy. Consequently, the sample had the typical features of a severe attack.

In summary, data from this pooled analysis suggest a poor performance of heart and respiratory rates as determinants of acute asthma severity. In the near future, these findings should be reflected in the recommendations of the most important asthma guidelines regarding the management of acute asthma.

References

- [1] McFadden Jr ER. Acute severe asthma. *Am J Respir Crit Care Med* 2003;168:740–59.
- [2] Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults. A review. *Chest* 2004;125:1081–102.
- [3] Aldington S, Beasley R. Asthma exacerbations 5: assessment and management of severe asthma in adults in hospital. *Thorax* 2007;62:447–58.
- [4] Camargo CA, Rachelefsky G, Schatz M. Managing asthma exacerbations in the emergency department summary of the National Asthma Education and Prevention Program Expert Panel Report 3 Guidelines for the Management of Asthma Exacerbations. *Proc Am Thorac Soc* 2009;6:357–66.
- [5] Hodder R, Loughheed MD, Rowe BH, FitzGerald JM, Kaplan AG, McIvor RA, et al. Management of acute asthma in adults in the emergency department: nonventilatory management. *CMAJ* 2010;182:E55–67.
- [6] Lazarus SC. Emergency treatment of asthma. *N Engl J Med* 2010;363:755–64.
- [7] Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2015 http://www.ginasthma.org/local/uploads/files/GINA_Report_2015.pdf. [Accessed April 14, 2015].
- [8] British Thoracic Society Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma a national clinical guideline revised May 2011. <http://www.sign.ac.uk/pdf/SIGN141.pdf>. [Accessed April 14, 2015].
- [9] Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. *Am J Respir Crit Care Med* 1998;157:698–703.
- [10] Rodrigo GJ, Rodrigo C. First-line therapy for adult acute asthma patients with a multiple dose protocol of ipratropium bromide plus albuterol on the emergency department. *Am J Respir Crit Care Med* 2000;161:1862–8.
- [11] Rodrigo GJ, Rodrigo C. Rapid-onset asthma attack: a prospective cohort study about characteristics and response to emergency department treatment. *Chest* 2000;118:1547–52.
- [12] Rodrigo GJ, Rodrigo C. Triple inhaled drug protocol for the treatment of acute severe asthma. *Chest* 2003;123:1908–15.
- [13] Rodrigo GJ, Peregalli V, Rodríguez Verde M, Rodrigo C. The effects of short term 28 and 100 percent oxygen on arterial carbon dioxide tension and peak expiratory flow rate in acute asthma. A randomized trial. *Chest* 2003;124:1312–7.
- [14] Rodrigo GJ. Comparison of inhaled fluticasone with IV hydrocortisone in the treatment of adult acute asthma. *Am J Respir Crit Care Med* 2005;171:1231–6.
- [15] Rodrigo GJ, Plaza V. Body mass index and response to emergency department treatment among adults with severe asthma exacerbations: a prospective cohort study. *Chest* 2007;132:1513–9.
- [16] Carden DL, Nowak RM, Sarkar D, Tomlanovich MC. Vital signs including pulsus paradoxus in the assessment of acute bronchial asthma. *Ann Emerg Med* 1983;12:80–3.
- [17] Reid J, Marciniuk D, Cockcroft D. Asthma management in the emergency department. *Can Respir J* 2000;7:255–60.
- [18] Silverman RA, Flaster E, Enright PL, Simonson SG. FEV₁ performance among patients with acute asthma. *Chest* 2007;131:164–71.
- [19] Strauss L, Hegal R, Galan G, Dixon L, McFadden Jr ER. Observations on the effects of aerosolized albuterol in acute asthma. *Am J Respir Crit Care Med* 1997;155:454–8.
- [20] Rodrigo C, Rodrigo G. Therapeutic response patterns to high and cumulative doses of salbutamol in acute severe asthma. *Chest* 1998;113:593–8.
- [21] Birring SS, Heartin E, Williams TJ, Brightling CE, Pavord ID. Peak expiratory flow sequence in acute exacerbations of asthma. *BMJ* 2001;322:281.
- [22] Kelly AM, Kerra D, Powell C. Is severity assessment after one hour of treatment better for predicting the need for admission in acute asthma? *Respir Med* 2004;98:777–81.
- [23] Rodrigo G, Rodrigo C. A new index for early prediction of hospitalization in patients with acute asthma. *Am J Emerg Med* 1997;15:8–13.
- [24] Rodrigo G, Rodrigo C. Early prediction of poor response in acute asthma patients in the emergency department. *Chest* 1998;114:1016–21.